x

The evaluation of the efficacy and safety of (PAC-EX01: EstroG-100)on menopausal symptoms: 12 weeks, multi-center, a randomized, double blind placebo-controlled clinical study

Shield Healthcare > Castro G 100 > The evaluation of the efficacy and safety of (PAC-EX01: EstroG-100)on menopausal symptoms: 12 weeks, multi-center, a randomized, double blind placebo-controlled clinical study
  • Conducted by: Ajou University Medical Center, Korea
  • Description:The results showed that EstroG-100 was significantly more effective than placebo in reducing the severity of menopausal symptoms. Participants in the EstroG-100 group reported a significant improvement in hot flashes, night sweats, vaginal dryness, and mood symptoms compared to those in the placebo group. Additionally, EstroG-100 was well-tolerated, with no serious adverse events reported. The study concluded that EstroG-100 could be a safe and effective treatment for menopausal symptoms.

Recent Post

Menu